GlobeNewswire

InnoStudio Continues To Push Chemistry Towards The Stars

Dela

Space Chemistry Special Session to be held at International Astronautical Congress for first time

 

BUDAPEST, Hungary and BOSTON, May 10, 2018 (GLOBE NEWSWIRE) -- InnoStudio is pleased to announce that its proposal for holding a Special Session on Space Chemistry at the 69th International Astronautical Congress entitled "Space Chemistry: a Key to Fostering Space Exploration" has been accepted. This is the first time that a special session on this topic will be held at such a prestigious event. The congress will take place in Bremen, Germany between the 1st and 5th October 2018.  The above special session will be held as part of the technical programme. We believe that the acceptance of this topic as a special session greatly emphasizes the importance of Space Chemistry for the future of the Space Industry.

IAC2018 Special Sessions are to supplement the regular technical programme of the congress and provide a sample of the state-of-the-art research and development in both academia and industry in special, novel, challenging and emerging topics in the field of space. Special Sessions emphasize multi-disciplinary and transversal aspects, as well as cutting-edge topics of space exploration.

The list of accepted Special Sessions can be found at http://www.iafastro.org/events/iac/iac- 2018/technical-programme/special-sessions/.

We are also happy to announce that InnoStudio's experts will give a presentation at the 3rd Space Chemistry Symposium - "Chemistry in Space & Past, Present & Future", which will be held on the 254th ACS National Meeting & Exposition between 19th and 23rd August 2018 in Boston, US.

The topics of the symposium will cover a wide range of pioneering chemistry technologies from space perspectives, including flow chemistry, nanomaterials and new platforms for microgravity research onboard the International Space Station. These innovations are expected to make an essential contribution towards facilitating space exploration missions and human expeditions.

Finally, a perspective article written by InnoStudio's space experts was published in the Journal of Flow Chemistry. The paper summarizes the state of the art of space chemistry, analyzes the suitability of flow chemistry in an extraterrestrial environment, and discusses some of the challenges and opportunities in space chemistry.

Read the article here: https://akademiai.com/doi/pdf/10.1556/1846.2017.00033

For more information please contact Richard Jones, CEO: richard.jones@innostudio.org

About InnoStudio Inc.

InnoStudio Inc. was founded in 2013 as a spin-off of Cominnex Inc. The companies belong to Darholding, which is a leading innovation house specialized on innovative spin-out companies. The three pillars of success are: a strong scientific background, a wide network of relationships with top companies and a special management approach.

InnoStudio Inc. is specialized in innovating on high risk, high gain fields with high importance such as:

· Nanotechnology: applying dynamic flow systems for generating nanoparticles, primarily for life science and chemistry related fields. e.g. Innostudio formulates first-tier agrochemical substances in collaboration with Agrothetis Inc.

· Artificial Intelligence and Chemometrics: adapting them for developing software solutions needed by sister corporations in the Darholding network and other users for pharma and bioscience related discovery, flow chemistry, microfluidics and nanotechnology.

· Improving bioavailability of natural products: adapting complex physicochemical solutions, including nanotechnology, for enhancing and optimizing skin penetration of natural products in aromatherapy, cosmetics and other flavour and fragrance fields.

· Space Chemistry: bringing experimental chemistry to space by incubating a research and development team of specialists.

Together with two other companies of the Darholding network, ThalesNano Inc. and ComInnex Inc.  the Space Chemistry Studio of InnoStudio is working on the Space Chemistry Project for shaping the future of chemistry in space. The Space Chemistry Project was founded by the Flow Chemistry Society on Switzerland in 2014 for bringing chemistry to the space. Today it has more than 40 members from 5 continents. (http://spaceflow.org/)




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: InnoStudio Inc. via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Oboya signs a cooperation agreement with Gaia regarding biomaterials13.12.2018 11:41Pressmeddelande

Oboya Horticulture Industries AB (publ) ("Oboya") has signed an important and long-term cooperation agreement on environmentally friendly biomaterials with Gaia Biomaterials AB ("Gaia") in Helsingborg, Sweden. The agreement means that Oboya uses Gaias biomaterials for the production and development of environmentally friendly cultivation products for the cultivation industry. Oboya has been actively involved in innovation, environmental and sustainability issues in recent years, and our goal is to encourage environmental and sustainability in the cultivation industry by offering environmentally friendly cultivation products to our customers. Oboya believes that the use of biomaterials will be important for success in the conversion to a fossil-free cultivation industry worldwide. The cooperation agreement means that Oboya uses Gaias biomaterials in its production and that through Gaias expertise we can develop new environmentally friendly cultivation products. Gaias biomaterials are bi

Oboya tecknar ett samarbetsavtal med Gaia avseende biomaterial13.12.2018 11:41Pressmeddelande

Oboya Horticulture Industries AB (publ) ("Oboya") har tecknat ett viktigt och långsiktigt samarbetsavtal avseende miljövänligt biomaterial med Gaia Biomaterials AB ("Gaia") i Helsingborg, Sverige. Avtalet innebär att Oboya använder Gaias biomaterial för tillverkning och utveckling av miljövänliga odlingsprodukter till odlingsindustrin. Oboya har under de senaste åren arbetat aktivt med innovation, miljö- och hållbarhetsfrågor och vårt mål är att främja miljö och hållbarhet inom odlingsindustrin genom att erbjuda miljövänliga odlingsprodukter till våra kunder. Oboya anser att användningen av biomaterial kommer att vara viktigt för framgång i omställningen till en fossilfri odlingsindustri världen över. Samarbetsavtalet innebär att Oboya använder Gaias biomaterial i sin produktion och att vi genom Gaias kompetens kan utveckla nya miljövänliga odlingsprodukter. Gaias biomaterial är biologiskt nedbrytbart, komposterbart samt ger upp till 80 % lägre koldioxidutsläpp vid förbränning jämfört

Stillfront: Simutronics reclaims publishing services10.12.2018 14:11Pressmeddelande

PRESS RELEASE December 10, 2018 Simutronics reclaims the publishing services for SIEGE: Titan Wars globally except China Simutronics Corp, a studio within Stillfront Group AB, has ended a co-publishing agreement regarding the mobile game SIEGE: Titan Wars with New York based publishing partner Tilting Point. According to a new agreement, Tilting Point will continue to provide publishing services and market the game in China but Simutronics will run the publishing services and marketing globally from the Group going forward. Simutronics is a leading developer of online roleplaying and mobile games such as DragonRealms, GemStone IV and Lara Croft Relic Run, the latter with more than 23 million downloads. Tilting Point is a new-generation games partner that provides top development studios with expert resources, services, and operational support to optimize high quality live games for success. "I am very pleased to continue the partnership with Tilting Point for the Chinese market as this

Stillfront: Simutronics återtar förläggartjänster10.12.2018 14:11Pressmeddelande

PRESSMEDDELANDE 2018-12-10 Simutronics återtar förläggartjänster för SIEGE: Titan Wars globalt med undantag för Kina Simutronics, en studio inom Stillfront Group, har avslutat ett medförläggaravtal avseende mobilspelet SIEGE: Titan Wars med den New York-baserade förläggarpartnern Tilting Point. Enligt ett nytt avtal kommer Tilting Point fortsatt att tillhandahålla förläggartjänster och marknadsföring av spelet i Kina men på global nivå kommer Simutronics att ansvara för förläggartjänster och marknadsföring av spelet från gruppen. Simutronics är en ledande utvecklare av rollspel och mobila spel som till exempel DragonRealms, GemStone IV och Lara Croft Relic Run, den sistnämnda med mer än 23 miljoner nedladdningar. Tilting Point är den nya generationens spelbolagspartner som förser ledande utvecklingsstudios med expertis, tjänster och operationell support för att optimera högkvalitativa livespel framgångsrikt. "Jag är mycket nöjd över det fortsatta partnerskapet med Tilting Point för den

Karolinska Development's portfolio company Aprea Therapeutics presents continued positive results from a Phase Ib/II study of APR 2462.12.2018 18:00Pressmeddelande

STOCKHOLM, December 2, 2018. Karolinska Development's portfolio company Aprea Therapeutics today presented positive clinical results for its drug candidate APR 246 at the 2018 American Society of Hematology (ASH) Annual Meeting in San Diego, US. An Overall Response Rate of 95% and a Complete Remission (CR) rate of 70% were achieved in an ongoing Phase I/II combination study of APR 246 and azacitidine (AZA) for the treatment of TP53 mutated Myelodysplastic Syndrome (MDS). No dose-limiting toxicities have been observed. Based on these encouraging data, Aprea intends to progress APR 246 into a Phase III study in the near future. The results presented at the ASH meeting is based on 20 patients with TP53 mutated MDS. The overall response rate was 95%, and 14 (70%) patients achieved a complete remission at data cutoff. These findings were accompanied by a deep molecular remission in the majority of patients as assessed by serial TP53 analysis. No dose-limiting toxicities have been experience

Karolinska Development's portfolio company Aprea Therapeutics presents continued positive results from a Phase Ib/II study of APR 2462.12.2018 18:00Pressmeddelande

STOCKHOLM, December 2, 2018. Karolinska Development's portfolio company Aprea Therapeutics today presented positive clinical results for its drug candidate APR 246 at the 2018 American Society of Hematology (ASH) Annual Meeting in San Diego, US. An Overall Response Rate of 95% and a Complete Remission (CR) rate of 70% were achieved in an ongoing Phase I/II combination study of APR 246 and azacitidine (AZA) for the treatment of TP53 mutated Myelodysplastic Syndrome (MDS). No dose-limiting toxicities have been observed. Based on these encouraging data, Aprea intends to progress APR 246 into a Phase III study in the near future. The results presented at the ASH meeting is based on 20 patients with TP53 mutated MDS. The overall response rate was 95%, and 14 (70%) patients achieved a complete remission at data cutoff. These findings were accompanied by a deep molecular remission in the majority of patients as assessed by serial TP53 analysis. No dose-limiting toxicities have been experience

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum